FDA Shows Skin Authority Who’s Boss In Warning For Drug Claims
This article was originally published in The Tan Sheet
Another skin care marketer, Skin Authority, receives an FDA warning letter for excessive product claims making its offerings drugs. The agency cites statements touting the firm’s ingredient benefits, including collagen production, improved circulation, inflammation relief and hyperpigmentation treatment, consistent with recent warnings issued to other cosmetics firms.
You may also be interested in...
FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.
Rep. Frank Pallone, D-N.J., reintroduces his bill proposing a ban on personal-care products containing synthetic plastic microbeads; Oregon legislation would require ingredient reporting and reformulations from manufacturers of children’s cosmetics containing flagged chemicals. More regulatory news.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.